USPTO Examiner SMITH EMILIE ALINE - Art Unit 1686

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19268839SCHEDULING METHOD FOR DAILY ECOLOGICAL FLOW VARIATION OF RIVER REACH BASED ON FISH HABITAT SUITABILITY OVERLAP RATEJuly 2025February 2026Abandon710NoNo
18929229MACHINE-LEARNING VIRTUALIZATION-ENABLED HARVESTINGOctober 2024December 2025Allow1421NoNo
18824839System and Method for Planning and Simulating a Surgical Operation to Create a Patient-Specific Spinal ImplantSeptember 2024March 2025Allow611YesNo
18692344ANALYTIC PLATFORM USING NPM1-ASSOCIATED GENES INTERACTION NETWORK FOR IDENTIFYING GENETIC TRAITSMarch 2024April 2025Abandon1310NoNo
18422789Systems and Methods for Correcting for Noise and Systemic Variations in Sequencing DataJanuary 2024March 2026Allow2630YesNo
18163149MARKERS FOR THE EARLY DETECTION OF COLON CELL PROLIFERATIVE DISORDERSFebruary 2023March 2025Allow2540YesNo
17805147METHODS, SYSTEMS, AND COMPUTER READABLE MEDIA FOR IMPROVING BASE CALLING ACCURACYJune 2022May 2025Abandon3530NoNo
17761046Methods for Predicting Patient Response to DMARDsMarch 2022March 2026Allow4811NoNo
17584074APPARATUS AND METHOD FOR DIAGNOSING CANCER USING LIQUID BIOPSY DATAJanuary 2022February 2026Abandon4810NoNo
17529694NORMALIZING TUMOR MUTATION BURDENNovember 2021March 2025Allow4040NoNo
17442465IDENTIFICATION OF CONVERGENT ANTIBODY SPECIFICITY SEQUENCE PATTERNSSeptember 2021February 2026Allow5320YesNo
17464561SYSTEMS AND METHODS FOR IDENTIFYING CELLS THAT ARE ANTIGEN-SPECIFIC FOR AN IMMUNOGENIC FEATURESeptember 2021November 2025Allow5040YesNo
17387830METHODS AND SYSTEMS FOR ADJUSTING TUMOR MUTATIONAL BURDEN BY TUMOR FRACTION AND COVERAGEJuly 2021December 2024Allow4140NoNo
17415266METHOD FOR ESTIMATING THE EFFECTIVENESS OF A TREATMENT BY AN ANTI-TNF ALPHA AGENT IN A PATIENT SUFFERING FROM RHEUMATOID ARTHRITIS AND HAVING AN INADEQUATE RESPONSE TO AT LEAST ONE BIOTHERAPYJune 2021October 2025Abandon5210NoNo
17304066METHOD, APPARATUS AND COMPUTER PROGRAM PRODUCT FOR PROVIDING A MULTI-OMICS FRAMEWORK FOR ESTIMATING TEMPORAL DISEASE TRAJECTORIESJune 2021March 2025Allow4520YesNo
17299155METHOD AND DATA PROCESSING APPARATUS FOR GENERATING REAL-TIME ALERTS ABOUT A PATIENTJune 2021August 2025Abandon5110NoNo
17317204DNA CANVAS FOR INFORMATION STORAGE AND NANOFABRICATIONMay 2021January 2026Allow5611NoNo
17224496HARDWARE ACCELERATED K-MER GRAPH GENERATIONApril 2021October 2025Allow5521YesNo
17281707METHOD AND SYSTEM OF TARGETING EPITOPES FOR NEOANTIGEN-BASED IMMUNOTHERAPYMarch 2021May 2025Allow5020YesNo
17212195EVALUATING METHOD, CALCULATING METHOD, EVALUATING APPARATUS, CALCULATING APPARATUS, EVALUATING PROGRAM, CALCULATING PROGRAM, RECORDING MEDIUM, EVALUATING SYSTEM, AND TERMINAL APPARATUS FOR MILD COGNITIVE IMPAIRMENTMarch 2021October 2025Abandon5521YesNo
17207169MACHINE LEARNING DRIVEN GENE DISCOVERY AND GENE EDITING IN PLANTSMarch 2021November 2024Allow4430YesNo
17205395POINT-OF-CARE TESTING (POCT) INSTRUMENT AND POCT SYSTEMMarch 2021January 2026Allow5830YesNo
17191078MULTI-LEVEL MACHINE LEARNING FOR PREDICTIVE AND PRESCRIPTIVE APPLICATIONSMarch 2021December 2025Allow5831YesNo
17180573SYSTEMS AND METHODS FOR VISUALLY GUIDING BONE REMOVAL DURING A SURGICAL PROCEDURE ON A JOINTFebruary 2021August 2025Allow5421YesNo
17262311ARRAY BASED METHOD AND KIT FOR DETERMINING COPY NUMBER AND GENOTYPE IN PSEUDOGENESJanuary 2021August 2025Abandon5420NoNo
17261707Method of Performing Differential Diagnosis of Neurodegenerative Diseases in a SubjectJanuary 2021March 2025Abandon5010NoNo
17128298ELECTRON DENSITY ESTIMATION METHOD, ELECTRON DENSITY ESTIMATION APPARATUS, AND RECORDING MEDIUMDecember 2020June 2025Abandon5421YesNo
17126491Merging Alignment and Sorting to Optimize Computer Operations for Gene Sequencing PipelineDecember 2020May 2025Allow5320YesNo
17112956Rapid Detection of Gene FusionsDecember 2020April 2025Allow5230YesNo
15734674SYSTEM, METHOD, AND COMPUTER PROGRAM PRODUCT FOR PREDICTING PROPERTIES OF A POLYMERDecember 2020December 2024Abandon4910NoNo
17074984CALCULATING CELL-TYPE RNA PROFILES FOR DIAGNOSIS AND TREATMENTOctober 2020December 2025Allow6021NoNo
17068311SYSTEMS AND METHODS FOR IDENTIFYING POSITIVE ALLOSTERIC MODULATORS OF ENZYMES TO ENHANCE ACTIVITYOctober 2020February 2025Allow5220YesNo
17065233SYSTEMS AND METHODS FOR GENOME ANALYSIS AND VISUALIZATIONOctober 2020November 2025Abandon6041NoNo
17040620METHODS FOR SCREENING A SUBJECT FOR THE RISK OF CHRONIC KIDNEY DISEASE AND COMPUTER-IMPLEMENTED METHODSeptember 2020January 2025Abandon5220NoNo
16982290COSMOPLEX: SELF-CONSISTENT SIMULATION OF SELF-ORGANIZING SYSTEMSSeptember 2020May 2025Allow5630NoNo
17018274SYSTEMS AND METHODS FOR FULLY AUTOMATED PROTEIN ENGINEERINGSeptember 2020October 2025Allow6010NoNo
17014809METHODS FOR IDENTIFICATION OF GENES AND GENETIC VARIANTS FOR COMPLEX PHENOTYPES USING SINGLE CELL ATLASES AND USES OF THE GENES AND VARIANTS THEREOFSeptember 2020January 2026Abandon6051YesNo
16990464SCORING VARIANTS IN AN EXOME TO PREDICT AN EFFECT OF THE VARIANTS ON GENE FUNCTIONAugust 2020May 2025Abandon5740NoNo
16945052METHODS FOR CONTROL OF A SEQUENCING DEVICEJuly 2020March 2025Abandon5540NoNo
16943951Methods and Systems for Identification of Human Leukocyte Antigen Peptide Presentation and Applications ThereofJuly 2020January 2026Allow6020YesNo
16963803EXERCISE LOAD ESTIMATION METHOD, EXERCISE LOAD ESTIMATION DEVICE, AND RECORDING MEDIUMJuly 2020April 2025Abandon5730NoNo
16908581DEVICES AND METHODS FOR GENOME SEQUENCINGJune 2020December 2024Allow5340YesNo
16904582TUMOR NEOANTIGEN PREDICTION PLATFORM AND APPLICATION THEREOF IN NEOANTIGEN VACCINE DEVELOPMENT SYSTEMJune 2020September 2025Abandon6041YesNo
16853347RESOLVING GENOME FRACTIONS USING POLYMORPHISM COUNTSApril 2020September 2025Abandon6041YesNo
16652555DETERMINING FUNCTIONAL STATUS OF IMMUNE CELLS TYPES AND IMMUNE RESPONSEMarch 2020June 2025Allow6050NoNo
16749737Pharmacogenomic Decision Support for Modulators of the NMDA, Glycine, and AMPA ReceptorsJanuary 2020February 2024Allow4930YesNo
16653564Re-writable DNA-Based Digital Storage with Random AccessOctober 2019January 2025Allow6020YesNo
16532077SYSTEMS AND METHODS FOR STORING AND READING NUCLEIC ACID-BASED DATA WITH ERROR PROTECTIONAugust 2019September 2024Allow6031YesNo
16478818NEOANTIGENS AND USES THEREOF FOR TREATING CANCERJuly 2019November 2024Allow6031NoNo
16345367SYSTEMS AND METHODS FOR ULTRA-FAST IDENTIFICATION AND ABUNDANCE ESTIMATES OF MICROORGANISMS USING A KMER-DEPTH BASED APPROACH AND PRIVACY-PRESERVING PROTOCOLSApril 2019August 2024Allow6041YesNo
16307817SYSTEMS AND METHODS FOR INTERPOLATION IN SYSTEMS WITH NON-LINEAR QUANTIZATIONDecember 2018October 2024Abandon6041NoNo
14895746BIOINFORMATIC PROCESSES FOR DETERMINATION OF PEPTIDE BINDINGDecember 2015March 2025Allow60131NoNo

Appeals Overview

No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.

Examiner SMITH, EMILIE ALINE - Prosecution Strategy Guide

Executive Summary

Examiner SMITH, EMILIE ALINE works in Art Unit 1686 and has examined 43 patent applications in our dataset. With an allowance rate of 62.8%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 55 months.

Allowance Patterns

Examiner SMITH, EMILIE ALINE's allowance rate of 62.8% places them in the 23% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by SMITH, EMILIE ALINE receive 2.98 office actions before reaching final disposition. This places the examiner in the 86% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by SMITH, EMILIE ALINE is 55 months. This places the examiner in the 2% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +33.3% benefit to allowance rate for applications examined by SMITH, EMILIE ALINE. This interview benefit is in the 81% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 25.6% of applications are subsequently allowed. This success rate is in the 41% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 9.1% of cases where such amendments are filed. This entry rate is in the 9% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Petition Practice

When applicants file petitions regarding this examiner's actions, 160.0% are granted (fully or in part). This grant rate is in the 97% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 3% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 4% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.